AGL 38.50 Decreased By ▼ -0.06 (-0.16%)
AIRLINK 219.00 Increased By ▲ 11.23 (5.41%)
BOP 10.47 Increased By ▲ 0.41 (4.08%)
CNERGY 7.04 Decreased By ▼ -0.04 (-0.56%)
DCL 10.05 Increased By ▲ 0.06 (0.6%)
DFML 41.00 Decreased By ▼ -0.14 (-0.34%)
DGKC 104.80 Increased By ▲ 1.34 (1.3%)
FCCL 36.75 Increased By ▲ 0.40 (1.1%)
FFBL 92.01 Increased By ▲ 0.42 (0.46%)
FFL 14.56 Decreased By ▼ -0.04 (-0.27%)
HUBC 140.80 Increased By ▲ 1.37 (0.98%)
HUMNL 14.29 Increased By ▲ 0.19 (1.35%)
KEL 6.03 Increased By ▲ 0.06 (1.01%)
KOSM 7.72 Decreased By ▼ -0.14 (-1.78%)
MLCF 47.80 Increased By ▲ 0.52 (1.1%)
NBP 70.80 Decreased By ▼ -2.96 (-4.01%)
OGDC 229.40 Increased By ▲ 6.74 (3.03%)
PAEL 39.35 Increased By ▲ 1.24 (3.25%)
PIBTL 9.34 Increased By ▲ 0.07 (0.76%)
PPL 209.98 Increased By ▲ 4.13 (2.01%)
PRL 40.80 Increased By ▲ 0.95 (2.38%)
PTC 26.90 Increased By ▲ 0.28 (1.05%)
SEARL 110.98 Increased By ▲ 0.74 (0.67%)
TELE 9.16 Decreased By ▼ -0.07 (-0.76%)
TOMCL 38.60 Increased By ▲ 0.39 (1.02%)
TPLP 14.03 Increased By ▲ 0.26 (1.89%)
TREET 26.58 Increased By ▲ 0.13 (0.49%)
TRG 60.55 Increased By ▲ 0.01 (0.02%)
UNITY 34.30 Increased By ▲ 0.16 (0.47%)
WTL 1.86 Decreased By ▼ -0.02 (-1.06%)
BR100 12,431 Increased By 132.3 (1.08%)
BR30 39,391 Increased By 513.3 (1.32%)
KSE100 115,304 Increased By 442.8 (0.39%)
KSE30 36,350 Increased By 154.1 (0.43%)

The Pakistan Pharmaceutical Manufacturers' Association (PPMA) has warned the federal government that any decision to discontinue import of raw material of medicines from India will weaken the country's ability to fight the Covid-19.

The warning to this effect came as the PPMA office-bearers addressed a press conference here at the press club on Monday.

The PPMA representatives appealed to the federal government that it should continue with the existing arrangements of drugs' raw material import. Any decision to disrupt the international supply chains associated with the Pakistani pharmaceutical industry will lessen the ability of the country's medical practitioners to cure the Covid-19.

Speaking on the occasion, PPMA senior vice chairman Syed Farooq Bukhari said import of pharmaceutical raw material from India or from any other country was done under a well-regulated regime being overseen by the Drug Regulatory Authority of Pakistan and other relevant state agencies.

"We are in a state of war against Covid-19 with rising positive cases in Pakistan as the pharmaceutical industry is the backbone of national apparatus put in place to fight the menace of coronavirus," he said.

He said the vital inputs of the pharmaceutical industry should remain readily available to the drug manufacturers so that there was no shortage of essential medicines in the country during the current health emergency.

"From the day one of lockdown in the country, the pharmaceutical industry has been doing its best with continuing its production so that there is no shortage of medicines during the on-going health crisis," he said.

The PPMA senior vice chairman said the federal cabinet should not take any decision against the import of medicine raw material from India or from any other

country when there had been an unabated increase in Covid-19 patients in the country.

"It is unfortunate that the federal and provincial governments in the country have been in the process of setting up more and more quarantine centres, isolation facilities, and special hospital wards to accommodate the Covid-19 cases but along with this we also need a constant supply of essential medicines to treat the patients of coronavirus," he said.

"For this, it is mandatory that the pharmaceutical industry of Pakistan should continue with its operations to its full capacity as for this we need a constant supply of raw material from our international clients," he said.

Bukhari said the federal cabinet should realize that raw material of medicines was being imported from India under a well-regulated and highly supervised regime keeping in view the constant needs of the pharmaceutical industry.

The decision had been taken last year to allow the import of the drugs' raw material from India due to the fact that in absence of such an arrangement there would be an acute shortage of essential medicines in the market or otherwise their prices would increase manifold. There was also the chance of emergence of a black market of medicines if the regular import of the raw material from the neighbouring country was discontinued, he said.

He said a very few medicines in the finished form were imported from India as they fall under the category of the life-saving drugs including vaccines required in the country to treat life-threatening situations including dog and snake bites.

The import of pharmaceutical raw material from India is being done under a proper SRO no 429 approved both by ministries of Commerce and National Health Services, he said.

The PPMA office-bearers appealed to the Prime Minister Imran Khan and his special assistant on National Health Services not to take any decision against the import of therapeutic goods from India or from any other country in view of the highly critical situation of Covid-19 in Pakistan.

The essential medicines are also constantly required to treat other infectious and lethal diseases in the country during this national emergency, they said.

PPMA zonal chairman (South) Iqbal Ahmad, former central chairmen Dr Kasier Waheed, and Zahid Saeed also spoke on the occasion.

Copyright Business Recorder, 2020

Comments

Comments are closed.